Form 4: Director Sara Ortwein Receives Sanara MedTech Stock Grant

Director Sara N. Ortwein was granted 4,616 shares of restricted common stock by Sanara MedTech Inc.

Summary

• Director Sara N. Ortwein acquired 4,616 shares of common stock in Sanara MedTech Inc. (SMTI).
• The shares were granted as restricted stock under the 2024 Omnibus Long-Term Incentive Plan.
• The grant has a zero-dollar acquisition price.
• Following this transaction, the director's total beneficial ownership is 25,415 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Retention incentive provided to a key board member.

Negatives

• Minor dilution of existing shareholders due to the issuance of new restricted stock.

Risks

• Vesting is contingent upon the director providing continued services to the issuer through the vesting date.

Future Outlook

The restricted stock is scheduled to vest on the earlier of the 2027 annual shareholder meeting or June 4, 2027.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to align board incentives with long-term shareholder value in the medical technology sector.

Comparison to Industry Standards

• The use of an Omnibus Long-Term Incentive Plan is consistent with standard compensation practices for mid-cap medical technology companies.
• Director equity grants are a common mechanism for board compensation in the U.S. healthcare sector.

Stakeholder Impact

• Shareholders: Minor dilution impact.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of the 4,616 shares on or before June 4, 2027.

Key Dates

Keywords

Sanara MedTech, SMTI, Form 4, Insider Trading, Director Compensation, Equity Grant